# A Study to Evaluate the Efficacy and Safety of Ensifentrine for 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

> **NCT05743075** · PHASE3 · COMPLETED · sponsor: **Nuance Pharma (shanghai) Co., Ltd** · enrollment: 526 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Ensifentrine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05743075
- **Lead sponsor:** Nuance Pharma (shanghai) Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-10
- **Primary completion:** 2024-12-06
- **Final completion:** 2025-03-07
- **Target enrollment:** 526 (ACTUAL)
- **Last updated:** 2025-06-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05743075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05743075, "A Study to Evaluate the Efficacy and Safety of Ensifentrine for 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05743075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*